A Tireless Minority

"DNA Damage Reponse Pathway" CANCER COMPANY to go PUBLIC IN USA
Apr 7, 2021 09:47 ET
Rain Therapeutics, a Newark, Calif.-based Phase 3-ready biotech developing in-licensed therapies for cancer, filed on Friday with the SEC to raise up to $100 million in an initial public offering.